Assessment of prognostic and diagnostic value of some biomarkers in hepatocellular carcinoma

• Published in: Experimental oncology Vol. 42; no. 3; p. 208
• Main Authors: Çavuş, B, Akyuz, F, İliaz, R, Akyuz, U, Duranyıldız, D, Serilmez, M, Tekin, D, Evirgen, S, Karaca, Ç, Demir, K, Beşışık, F, Kaymakoğlu, S
• Format: Journal Article
• Language: English
• Published: Ukraine 01.09.2020
• Subjects: Biomarkers, Tumor; Blood Chemical Analysis; Blood Proteins; Carcinoma, Hepatocellular - blood; Carcinoma, Hepatocellular - diagnosis; Carcinoma, Hepatocellular - etiology; Carcinoma, Hepatocellular - mortality; Case-Control Studies; Enzyme-Linked Immunosorbent Assay; Female; Galectins - blood; Humans; Interferons - blood; Interleukins - blood; Liquid Biopsy - methods; Liver Neoplasms - blood; Liver Neoplasms - diagnosis; Liver Neoplasms - etiology; Liver Neoplasms - mortality; Male; Prognosis; ROC Curve; Survival Rate
• ISSN: 2312-8852

Hepatocellular carcinoma (HCC) is an increasing problem worldwide. Determining a prognosis is important for the management of HCC. We aimed to investigate the impact of interleukin (IL)-29, galectin-3, leptin, fibronectin and protease-activated receptor-1 on the prognosis and diagnosis of patients with HCC. 60 HCC patients (75% male) and 20 healthy volunteers (70% male) were enrolled in this prospective study. Serum samples were obtained during the first admission before any adjuvant or metastatic treatments were administered. Serum biomarkers were determined using ELISA kits. All patients had cirrhosis, and the Child - Pugh stages were as follows: 61.5% Child - Pugh A, 35.9% Child - Pugh B and 2.6% Child - Pugh C (61.7% hepatitis B virus, 11.7% hepatitis C virus, 6.7% hepatitis B virus + hepatitis C virus, 11.7% alcoholic and 8.3% cryptogenic). Fifty-three percent of the HCC patients died within a median of 7.5 months. The mean serum level of IL-29 in patients with HCC was higher than that in the control group (32.55 pg/ml vs 11.46 pg/ml, p < 0.015). Galectin-3 levels were significantly higher in the HCC group (6.7 ng/ml vs 1.38 ng/ml, p < 0.001). Fibronectin levels were higher in the control group than in the HCC group (260 635 ng/ml vs 257 353 ng/ml). However, the mean protease-activated receptor-1 and leptin levels were similar between the two groups (p > 0.05). The biomarkers were divided into two groups according to their median level. In the log rank analysis, biomarkers had no effect on survival (p > 0.05). IL-29 and galectin-3 levels were significantly higher in HCC patients. Although IL-29 and galectin-3 can be used as diagnostic markers for HCC, they had no prognostic value in HCC patients.